ProjectFLYSIN – Phase Ib/IIa study to evaluate the safety, tolerability preliminary effiacy of the Fc-optimized FLT3…
Basic data
Acronym:
FLYSIN
Title:
Phase Ib/IIa study to evaluate the safety, tolerability preliminary effiacy of the Fc-optimized FLT3 antibody FLYSIN for the treatment of acute myeloid leukemia patient with minimal residual disease
Duration:
08/05/2022 to 31/08/2022
Abstract / short description:
This is an open-label, single-arm, phase I trial to assess the safety and preliminary efficacy of the antibody FLYSIN in MRD positive AML patients as monotherapy. Entry of medical history in database.
Involved staff
Managers
Institute for Clinical Epidemiology and Applied Biometry
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Contact persons
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Cluster of Excellence: Image-Guided and Functionally Instructed Tumor Therapies (iFIT)
Centers or interfaculty scientific institutions
Centers or interfaculty scientific institutions
Faculty of Medicine
University of Tübingen
University of Tübingen
Local organizational units
Institute for Clinical Epidemiology and Applied Biometry
Hospitals and clinical institutes
Faculty of Medicine
Faculty of Medicine
Funders
Tübingen, Baden-Württemberg, Germany